Crescent Biopharma, Inc.
Ownership
Ownership Structure
Who owns Crescent Biopharma, Inc. (CBIO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 71.7% of the shares are freely tradable; institutional investors hold 79.4%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 11.13 | 4,133,514 | +0.0 | 03/31/2026 |
| Bvf Inc | 7.40 | 2,748,763 | +0.0 | 03/31/2026 |
| Fairmount Funds Management LLC | 7.40 | 2,747,866 | +0.0 | 03/31/2026 |
| VR Adviser, LLC | 5.74 | 2,133,576 | +0.0 | 03/31/2026 |
| Logos Global Management LP | 5.11 | 1,900,000 | +293.8 | 06/30/2026 |
| FCPM III SERVICES BV | 4.52 | 1,677,852 | +0.0 | 03/31/2026 |
| Balyasny Asset Management LLC | 4.07 | 1,510,033 | +1,251.7 | 03/31/2026 |
| Vestal Point Capital LP | 4.04 | 1,500,000 | +0.0 | 03/31/2026 |
| Opaleye Management Inc | 3.55 | 1,319,351 | +0.5 | 06/30/2026 |
| TANG CAPITAL MANAGEMENT LLC | 3.12 | 1,160,000 | +33.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Brumm Joshua T | Chief Executive Officer | 271,765 | 3,804,710 $ | Sep 18, 2026 | direct |
| McNeill Jonathan | President and COO | 134,588 | 1,884,232 $ | Sep 18, 2026 | direct |
| Pinkas Jan | Chief Scientific Officer | 21,581 | 302,134 $ | Sep 16, 2026 | direct |
| Im Ellie Eunkyung | Chief Medical Officer | 21,446 | 300,244 $ | Sep 16, 2026 | direct |
| Scalzo Richard William | Chief Financial Officer | 19,730 | 276,220 $ | Sep 16, 2026 | direct |
| Bispham Barbara Harlin | See Remarks | 18,710 | 261,940 $ | Sep 16, 2026 | direct |
| Lynch Ryan | See Remarks | 13,631 | 190,834 $ | Sep 16, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Brumm Joshua T | Chief Executive Officer | Sell | 7,837 | 16.71 | 130,956 |
| Sep 18, 2026 | McNeill Jonathan | President and COO | Sell | 3,839 | 16.71 | 64,150 |
| Sep 16, 2026 | Lynch Ryan | See Remarks | Sell | 240 | 17.90 | 4,296 |
| Sep 16, 2026 | Pinkas Jan | Chief Scientific Officer | Sell | 658 | 17.90 | 11,778 |
| Sep 16, 2026 | Im Ellie Eunkyung | Chief Medical Officer | Sell | 623 | 17.90 | 11,152 |
| Sep 16, 2026 | Scalzo Richard William | Chief Financial Officer | Sell | 568 | 17.90 | 10,167 |
| Sep 16, 2026 | Bispham Barbara Harlin | See Remarks | Sell | 620 | 17.90 | 11,098 |
| Sep 16, 2026 | Brumm Joshua T | Chief Executive Officer | Sell | 1,610 | 17.90 | 28,819 |
| Sep 16, 2026 | McNeill Jonathan | President and COO | Sell | 731 | 17.90 | 13,085 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.